Skip to main content
. 2021 Jun 10;16:4031–4044. doi: 10.2147/IJN.S303529

Figure 3.

Figure 3

Nanoparticle release profile, measured in SWF, and antibacterial activity against MRSA in vitro. (A) Release profile of PLGA BZK nanoparticles (B) L929 cell toxicity of nanoparticles in vitro. (C) Minimum inhibitory concentrations (MICs). (D) MBC results from an investigation BZK treatment using the following concentrations of the 1a–8a is 20, 15, 10, 7.5 5.0, 4.0, 3.33, 2.5 μg/mL of BZK nanoparticles, and 1b–8b is 20, 15, 10, 7.5 5.0, 4.0, 3.33, 2.5 μg/mL of BZK water solution. Error bars represent mean ± standard deviations of each experiment, conducted in triplicate.

Notes: ***p < 0.001 is an extremely significant difference, **p < 0.01 is a significant difference (n =3).